Media stories about Ziopharm Oncology (NASDAQ:ZIOP) have trended somewhat positive this week, Accern reports. Accern ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Ziopharm Oncology earned a coverage optimism score of 0.12 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 46.3540202198302 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
These are some of the headlines that may have effected Accern Sentiment’s analysis:
Shares of ZIOP stock traded down $0.03 on Friday, reaching $4.32. 1,032,982 shares of the company’s stock were exchanged, compared to its average volume of 1,057,706. Ziopharm Oncology has a 52 week low of $3.33 and a 52 week high of $7.88. The firm has a market capitalization of $619.43, a P/E ratio of -8.15 and a beta of 1.72.
Ziopharm Oncology (NASDAQ:ZIOP) last issued its quarterly earnings results on Thursday, March 1st. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.13). The business had revenue of $1.60 million for the quarter, compared to the consensus estimate of $1.59 million. During the same period in the prior year, the business posted ($0.11) earnings per share. Ziopharm Oncology’s revenue was up .0% on a year-over-year basis. equities research analysts anticipate that Ziopharm Oncology will post -0.53 earnings per share for the current fiscal year.
A number of equities research analysts recently issued reports on ZIOP shares. BidaskClub lowered Ziopharm Oncology from a “sell” rating to a “strong sell” rating in a research note on Thursday, January 11th. Zacks Investment Research reissued a “hold” rating on shares of Ziopharm Oncology in a research note on Saturday, January 13th. HC Wainwright set a $10.00 price target on Ziopharm Oncology and gave the stock a “buy” rating in a research note on Thursday, December 14th. ValuEngine lowered Ziopharm Oncology from a “sell” rating to a “strong sell” rating in a research note on Sunday, December 31st. Finally, Raymond James Financial reissued a “hold” rating on shares of Ziopharm Oncology in a research note on Monday, December 11th. Three investment analysts have rated the stock with a sell rating, one has given a hold rating and one has assigned a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $7.50.
ILLEGAL ACTIVITY NOTICE: This piece was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another site, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this piece can be read at https://www.dispatchtribunal.com/2018/04/07/ziopharm-oncology-ziop-earns-daily-news-sentiment-rating-of-0-12.html.
Ziopharm Oncology Company Profile
ZIOPHARM Oncology, Inc, a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to cancer; and Sleeping Beauty (SB), which is based on the genetic engineering of T-cells using the (SB) system to rapidly reprogram T-cells outside of the body for infusion.
Receive News & Ratings for Ziopharm Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ziopharm Oncology and related companies with MarketBeat.com's FREE daily email newsletter.